ADMP
Income statement / Annual
Last year (2022), Adamis Pharmaceuticals Corporation's total revenue was $4.76 M,
an increase of 115.34% from the previous year.
In 2022, Adamis Pharmaceuticals Corporation's net income was -$26.20 M.
See Adamis Pharmaceuticals Corporation’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
03/31/2014 |
03/31/2013 |
| Operating Revenue |
$4.76 M
|
$2.21 M
|
$16.53 M
|
$22.11 M
|
$15.09 M
|
$13.07 M
|
$6.47 M
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$6.19 M |
$6.87 M |
$14.89 M |
$15.48 M |
$9.80 M |
$7.42 M |
$4.85 M |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
-$1.43 M |
-$4.66 M |
$1.63 M |
$6.64 M |
$5.29 M |
$5.65 M |
$1.62 M |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
-0.3 |
-2.11 |
0.1 |
0.3 |
0.35 |
0.43 |
0.25 |
0 |
0 |
0 |
| Research and Development
Expenses |
$10.38 M
|
$11.26 M
|
$8.28 M
|
$10.38 M
|
$18.79 M
|
$7.53 M
|
$9.70 M
|
$4.84 M
|
$1.01 M
|
$1.21 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$13.25 M
|
$16.14 M
|
$30.58 M
|
$25.29 M
|
$25.95 M
|
$22.82 M
|
$17.13 M
|
$9.01 M
|
$3.39 M
|
$2.01 M
|
| Other Expenses |
-$1.87 M |
$7,216.00 |
$84,008.00 |
$0.00 |
$0.00 |
-$960,230.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$23.63 M |
$27.41 M |
$38.86 M |
$35.66 M |
$44.74 M |
$30.35 M |
$26.82 M |
$13.85 M |
$4.40 M |
$3.22 M |
| Cost And Expenses |
$29.82 M |
$34.28 M |
$53.76 M |
$51.14 M |
$54.54 M |
$37.77 M |
$31.68 M |
$13.85 M |
$4.40 M |
$3.22 M |
| Interest Income |
$44,126.00 |
$0.00 |
$0.00 |
$175,772.00 |
$245,403.00 |
$102,233.00 |
$9,285.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$44,126.00 |
$6,649.00 |
$159,628.00 |
$123,258.00 |
$157,765.00 |
$231,291.00 |
$214,396.00 |
$0.00 |
$8.63 M |
$2.33 M |
| Depreciation &
Amortization |
$791,337.00
|
$1.44 M
|
$3.69 M
|
$3.12 M
|
$3.10 M
|
$3.06 M
|
$2.53 M
|
$990,290.00
|
$296,123.00
|
$0.00
|
| EBITDA |
-$24.27 M
|
-$30.63 M
|
-$33.54 M
|
-$25.91 M
|
-$36.11 M
|
-$22.49 M
|
-$22.66 M
|
-$12.86 M
|
-$4.10 M
|
-$3.22 M
|
| EBITDA Ratio |
-5.1 |
-13.87 |
-2.03 |
-1.17 |
-2.39 |
-1.72 |
-3.5 |
0 |
0 |
0 |
| Operating Income Ratio
|
-5.27
|
-14.52
|
-2.25
|
-1.31
|
-2.62
|
-1.9
|
-3.89
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$1.14 M
|
-$2.53 M
|
$389,380.00
|
-$269,592.00
|
$87,638.00
|
-$1.09 M
|
$1.19 M
|
$278,431.00
|
-$3.76 M
|
-$3.85 M
|
| Income Before Tax |
-$26.20 M |
-$34.60 M |
-$49.39 M |
-$29.30 M |
-$39.38 M |
-$25.88 M |
-$24.01 M |
-$13.57 M |
-$8.16 M |
-$7.06 M |
| Income Before Tax Ratio
|
-5.51
|
-15.67
|
-2.99
|
-1.32
|
-2.61
|
-1.98
|
-3.71
|
0
|
0
|
0
|
| Income Tax Expense |
$2,000.00 |
$796.00 |
$2,174.00 |
$8,672.00 |
-$369,340.00 |
-$339,391.00 |
-$4.57 M |
$0.00 |
$8.63 M |
$130,000.00 |
| Net Income |
-$26.20 M |
-$34.60 M |
-$49.39 M |
-$29.31 M |
-$39.01 M |
-$25.54 M |
-$19.44 M |
-$13.57 M |
-$8.16 M |
-$7.19 M |
| Net Income Ratio |
-5.51 |
-15.67 |
-2.99 |
-1.33 |
-2.59 |
-1.95 |
-3 |
0 |
0 |
0 |
| EPS |
-12.24 |
-16.8 |
-44.57 |
-38.52 |
-69.86 |
-63.06 |
-77.75 |
-71.56 |
-77.72 |
-85.96 |
| EPS Diluted |
-12.24 |
-16.8 |
-44.57 |
-38.52 |
-69.86 |
-63.06 |
-77.75 |
-70.71 |
-76.19 |
-85.96 |
| Weighted Average Shares
Out |
$2.14 M
|
$2.06 M
|
$1.11 M
|
$760,913.00
|
$558,364.00
|
$404,990.00
|
$250,011.00
|
$189,654.00
|
$104,945.00
|
$83,697.00
|
| Weighted Average Shares
Out Diluted |
$2.14 M
|
$2.06 M
|
$1.11 M
|
$760,913.00
|
$558,364.00
|
$404,990.00
|
$250,011.00
|
$191,952.00
|
$107,043.00
|
$83,697.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
